Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of Talsaclidine in Alzheimer's Disease
NCT02248116Phase 3Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- May 1999
- Primary completion
- Sep 2000
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of talsaclidine in Alzheimer's disease (AD), sponsored by Boehringer Ingelheim. Started May 1999; status: terminated.
02
Drugs
talsaclidine
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02248116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02248116.